Merck & Company, Inc.
MRK NYSEThere isn't enough steady cash-flow history to value Merck & Company yet. Analysts' mean target is about 13% higher.
No single event this week: analyst targets span ~₹9,730–17.2K a share.
On consensus MRK is the cheapest of its peers, at ~16x next year's earnings. Otto can't build a cash-flow range for this one yet, so the range shown is the analysts' own; the price, ₹13.3K, sits inside it.
01 · Forward P/E
- MRK ~16x
- ABBV ~18.1x
- GILD ~16.5x
- JNJ ~24x
Next fiscal year's consensus earnings. P/E ÷ growth: MRK ~0.02, peers ~0.10–0.32.
02 · Latest event
No results, sharp move or standout headline in the last week.
03 · The range, a share
- Analyst targets ~₹9,730–17.2K
Current price ₹13.3K.
- ~16x
- Forward P/E, consensus
- ~0.02
- P/E per point of EPS growth
- ₹13.3K
- Price: inside the target range
- ~₹9,730–17.2K
- Analyst target range
Forward P/E and analyst targets: Yahoo Finance consensus. No cash-flow range: the company's reported cash flows don't support one yet. Not investment advice — Otto just crunches numbers.
Price trend
-8.0% over the last month · S&P 500 -9.4%
What think
The market's move: -8.0% over the past year
Trading 78% up its 52-week range. Price is the market's live vote — not advice.
Analyst consensus: Buy · 26 analysts
Average 12-month target ₹14,968.52 — +12.7% vs today.
Yahoo Finance's analyst aggregate. Sentiment, not advice.
Insiders: 0 buys · 0 sales in recent filings
Open-market trades from SEC Form 4. Sales are often pre-planned (10b5-1); buys tend to say more. Sentiment, not advice.
InvestRight readers: 0 watching
This site's own activity — not a broad measure. Sentiment, not advice.
Otto's still crunching Merck's numbers.
Select Refresh at the top of this page to pull the full statements now — it takes a few seconds.
Ownership & insiders
from SEC Form 4 filingsNo insider filings saved yet — Otto checks EDGAR on each refresh.
What does this show?
Buys and sells by the company's own directors and officers, from their SEC filings. Insiders sell for many reasons, but clusters of open-market buying can signal confidence.
Learn more on Investopedia →Spot a missing competitor? Sign in to add it — it'll show for everyone.
What does this show?
A few peers in the same business, each with its own mini snowflake, so you can see how this company stacks up rather than judging it in isolation. Anyone signed in can add a missing competitor — it shows for everyone, marked as user-added.
Learn more on Investopedia →In the news
- MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds
- How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine Data
- Merck (MRK) Stock Rallies As Q3 Earnings Ease Profit Squeeze
- Why Merck Stock Flew Higher on Friday
- Merck Stocks Rise 2.6% With Qlex Still Under 10% of Keytruda Sales
- Eli Lilly’s Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss Drugs
- CMMB Celebrates New Distribution Center at the Brethren Service Center with Ribbon-Cutting Ceremony
- This week in charts: ESMO’s winners and losers
My notes
Sign in to keep a private decision journal on this stock — only you can see your notes.
Hi! I can explain Merck's numbers — valuation, health, the dividend, the fair-value gap. What would you like to know?
Otto explains what's on this page — not investment advice.